Brief: Stoke Therapeutics Announces Landmark New Data That Support The Potential For STK-001 to be the First Disease-Modifying Medicine

Stoke Therapeutics

25/03/2024 20:04

March 25 (Reuters) - Stoke Therapeutics Inc  STOK.O :
    * STOKE THERAPEUTICS ANNOUNCES LANDMARK NEW DATA THAT
SUPPORT THE
POTENTIAL FOR STK-001 TO BE THE FIRST DISEASE-MODIFYING MEDICINE
FOR THE TREATMENT OF PATIENTS WITH DRAVET SYNDROME
    * STOKE THERAPEUTICS INC - STK-001 GENERALLY WELL-TOLERATED
    * STOKE THERAPEUTICS - 70MG DOSES SHOWED SUBSTANTIAL AND
SUSTAINED
REDUCTIONS IN CONVULSIVE SEIZURE FREQUENCY ON TOP OF AVAILABLE
ANTI-SEIZURE MEDICINES
    * STOKE THERAPEUTICS INC - MEDIAN REDUCTIONS OF 85% (N=10)
AT 3
MONTHS AND 74% (N=9) AT 6 MONTHS AFTER LAST DOSE
    * STOKE THERAPEUTICS -TO MEET REGULATORY AGENCIES TO DISCUSS
REGISTRATIONAL STUDY DESIGN WITH INITIAL DOSES OF 70MG FOLLOWED
BY CONTINUED DOSING AT 45MG
    * STOKE THERAPEUTICS INC - CLEARANCE FROM U.S. FDA FDA) THAT
ALLOWS PATIENTS TO RECEIVE THREE DOSES OF 70MG FOLLOWED BY
CONTINUED DOSING AT 45MG

Source text for Eikon:  ID:nBw9PhPJ8a 
Further company coverage:  STOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))